Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial
Journal of Digestive Diseases · 2024
DOI: 10.1111/1751-2980.13314 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Digestive Diseases, 2024. Verfasst von Xiao Quan Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Rifaximin, Liver Cirrhosis, Esophageal and Gastric Varices, Gastrointestinal Microbiome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: Fund of Clinical Research of Zhongshan Hospital, Fudan University, Innovation Fund of Science and Technology Commission of Shanghai Municipality, Shanghai Sailing Program, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Objectives
The application of rifaximin, a non‐absorbable antibiotic, in hepatic encephalopathy (HE) has been well established; however, its effect on other complications in cirrhotic patients with previous gastroesophageal variceal bleeding (GEVB) remains unclear. Therefore, we performed a pilot randomized controlled trial aiming to evaluate the impact of rifaximin on cirrhosis‐related complications and changes in gastric microbiota.
Methods
Eighty cirrhotic patients who received prophylactic endoscopic treatment for variceal rebleeding were randomly assigned to the control or rifaximin treatment group (rifaximin 400 mg twice daily for 8 weeks). Primary outcome was the total liver‐related score, consisting of changes in cirrhosis‐related complications including rebleeding, ascites, HE and portal vein thrombosis (PVT). The 16S rDNA sequencing analysis was conducted with gastric lavage fluid samples for the analysis of gastric microbiota.
Results
During the 8‐week follow‐up, the total liver‐related score decreased significantly upon rifaximin therapy (−0.35 ± 0.14 vs 0.05 ± 0.14, p = 0.0465) as well as serum C‐reactive protein (CRP) ( p = 0.019) and interleukin‐8 ( p = 0.025) compared with the control group. The rate of PVT recanalization was significantly higher in the rifaximin group ( p = 0.012). Prominent difference in gastric microbiota between the two groups was observed, and the rifaximin group had a higher abundance of several taxa which were dysregulated in the progression of cirrhosis. CRP was correlated with several taxa including Alphaproteobacteria, Rhizobiales and Collinsella.
Conclusions
Rifaximin may improve cirrhosis‐related complications, including PVT, in patients with previous GEVB through anti‐inflammatory and microbiota‐modulating functions. Trial registration number: NCT02991612.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Center of Evidence-Based Medicine, Fudan University, Shanghai, China.
- Department of Urology, Zhongshan Hospital, Fudan University, Shanghai, China.
- Department of Biostatistics, School of Public Health, Fudan University, Shanghai, China.
- Department of Ultrasound, Zhongshan Hospital, Fudan University, Shanghai, China.
- Endoscopy Center and Endoscopy Research Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Feng Li, Shi Yao Chen
Förderung
- Fund of Clinical Research of Zhongshan Hospital, Fudan University
- Innovation Fund of Science and Technology Commission of Shanghai Municipality
- Shanghai Sailing Program, Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Huang, X. Q., Ai, Y. J., Li, F., Ye, S. T., Wang, J. H., Zhang, R., Zhang, W., Zhu, Y. L., & Chen, S. Y. (2024). Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial. Journal of Digestive Diseases. https://doi.org/10.1111/1751-2980.13314
Vancouver
Huang XQ, Ai YJ, Li F, Ye ST, Wang JH, Zhang R, et al. Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial. Journal of Digestive Diseases. 2024. doi:10.1111/1751-2980.13314
BibTeX
@article{Huang2024,
author = {Huang, Xiao Quan and Ai, Ying Jie and Li, Feng and Ye, Si Tao and Wang, Jia Hao and Zhang, Rui and Zhang, Wei and Zhu, Yu Li and Chen, Shi Yao},
title = {Impact of rifaximin on cirrhosis complications and gastric microbiota in patients with gastroesophageal variceal bleeding: A pilot randomized controlled trial},
journal = {Journal of Digestive Diseases},
year = {2024},
doi = {10.1111/1751-2980.13314}
}
EUVIMED